Department of Gastroenterology, Indira Gandhi Institute of Medical Sciences, Patna, Bihar, India
 Research Article   
								
																Efficacy and Safety of Tenofovir Alafenamide in Treatment Naive Patients with Hepatitis B-Virus Related Decompensated Cirrhosis: A Prospective Observational Study 
																Author(s): Sanjeev Jha*, Ravikant Kumar, Saurabh Kumar, Ravi Keshri, Aditya V. Singh, Gaurav Kumar and Samir S. Bhagwat             
								
																
						 Background: The effect of Tenofovir Alafenamide (TAF) therapy on viral suppression and hepatic function in patients of Hepatitis B Virus (HBV) related decompensated cirrhosis is
    not known. Aim of this study was to evaluate the efficacy and safety of TAF therapy in these patients.
	Methods: We analyzed 55 consecutive HBV-infected treatment naive patients with decompensated cirrhosis treated with 25 mg/day TAF and evaluated the treatment outcomes.
    Treatment efficacy was evaluated by measuring virological, serological, biochemical responses and changes in hepatic function over period of 6 month.
	Results: At month 6, undetectable HBV-DNA level, HBeAg loss, HBeAg seroconversion and ALT normalization was seen in 65.2%, 22.2%, 5.5% and 74.5% patients respectively.
	  Virological and biochemical responses were simi.. Read More»
						  
																DOI:
								10.37421/cgj.2021.6.143															  
Clinical Gastroenterology Journal received 33 citations as per Google Scholar report